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Case presentation
A 38-year-old man was admitted to the University Hospital of Padova
6 years ago because of recurrent nephrolithiasis. The patient had been
in good health except for recurrent renal stones since 1971. He had
passed more than 15 stones from both sides, all spontaneously, except
for one that required a left ureterolithotomy. Chemical analysis of some
of the stones revealed calcium, oxalate, and phosphate. The patient had
no history of gastrointestinal disease, excessive sun exposure, or drug
use. Physical examination was normal. Laboratory studies revealed a
plasma urea of 30 mg/dl; serum creatinine, 1.1 mg/dl; uric acid, 4.6
mg/dl; calcium, 10.8 mg/dl; ionized calcium, 1.33 mmol/liter (normal,
<1.30); phosphate, 2.2 mg/dl; and C-terminal PTH, 0.4 ng/ml (normal
range, 0.2—0.8 ng/ml). Urine examination was normal. Calciuria was 490
mg/day; oxaluria, 47 mg/day; phosphaturia, 1357 mg/day; and uricos-
uria, 486 mg/day. Urinary cAMP was 5.13 mol/day (normal, <4.7). A
cyanide-nitroprusside test was negative. Radiographs of the chest,
abdomen, skull, and hands were normal, as were intravenous pyelog-
raphy and renal sonography. No stones were present. Osteodensitom-
etry revealed 75% bone mineralization in comparison with controls
matched for gender and age.
Primary hyperparathyroidism was strongly suspected despite the
normal blood PTH. Accordingly, a 203-technetium scintigram of the
parathyroids was obtained, which disclosed an increased tracer uptake
corresponding to the right lower thyroid lobe. Computed tomography
confirmed the presence of a mass behind the inferior half of the right
lobe of the thyroid gland, and venous sampling of the thyroid veins
demonstrated an increased concentration of PTH in the right lower
thyroid vein.
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At surgery, the lower right and upper left parathyroid glands were
removed, and a subtotal lobectomy was performed in the upper right
and lower left glands. Histologic examination revealed chief cell hyper-
plasm. After parathyroidectomy, the patient's blood and urinary cal-
cium and phosphate levels returned to normal. Urinary oxalate excre-
tion remained slightly increased (45 mg/day).
The patient remained in good health until 2 years ago, when he was
readmitted with right renal colic. At that time, his blood calcium was 9.7
mg/dl; phosphate, 3.4 mg/dl; and PTH, 0.7 ng/ml. The urinary calcium
was 262 mg/day and phosphate, 867 mg/day. Urinary cAMP was 1.9
mol/day. Urinary oxalate was again slightly increased (46 mg/day). An
abdominal plain film and ultrasonogram revealed a calcification in the
right kidney 4 mm in diameter. The patient subsequently passed this
stone. He was treated with hydrochlorothiazide and amiloride, and he
has had no further stones over the subsequent 2 years of observation.
The erythrocyte steady-state oxalate self-exchange was high at 1.80
x l0 min (normal, <0.55) six years ago and 1.88 x l02 min1 two
years ago.
Discussion
DR. ARTURO BORSATTI (Professor of Nephrology, University
of Padova School of Medicine; Chief, Division of Nephrology,
Institute of Internal Medicine, University Hospital, Padova,
Italy): This patient is unusual in that correction of hypercalci-
uria by parathyroidectomy was not sufficient to prevent subse-
quent renal stone formation. However, he also had a defect in
the cellular handling of oxalate, as suggested by a high steady-
state oxalate self-exchange in red blood cells and mild hyper-
oxaluria. The potential role of abnormal cellular handling of
oxalate in the pat hophysiology of calcium oxalate (CaOx) renal
stone disease will be the focus of this Forum. I first will
consider the problem of "mild hyperoxaluria" in renal stone
disease. Then I will review the role of oxalate as a stone
promoter, looking for the most reasonable cause of an increase
in urinary oxalate. Later I will describe a defect in oxalate
self-exchange found in red blood cells of stone formers, and
finally I will try to establish a hypothetical link between what
happens in erythrocytes and what might happen in the cells
involved in renal oxalate absorption and secretion.
Mild hyperoxaluria in idiopathic calcium oxalate
nephrolithiasis
In 1978 Williams stated that "In only a small percentage of
patients with recurrent calcium oxalate stones has it been
possible to demonstrate that urinary oxalate excretion is signif-
icantly elevated above the normal range" [11. Ten years later,
after the introduction of methods that measure urinary oxalate
more accurately, the same investigator asserted that ". . . most
recent studies of calcium oxalate stone formers. . . suggest that
the true incidence of hyperoxaluria is between 10 to 20 percent"
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[21. These two statements summarize the enormous method-
ologic and conceptual developments in renal stone disease that
have occurred over the last few years. Enhanced accuracy has
been achieved by the availability of enzymatic, ion chromato-
graphic, or high-performance liquid chromatographic methods
for the assay of oxalate in biologic fluids, as well as new
information about the collection and storage of samples [2, 31.
In the meantime, various theoretical, experimental, and clinical
observations have clarified the role of urinary oxalate in cal-
cium oxalate lithiasis. We now are quite confident that ". . . in
the formation of the CaOx stones, at the very least, oxalate is as
important as calcium and deserves equal attention [4].
Robertson and Peacock first reported that small increases of
oxalate excretion (40—100 mg/day) predisposed to the formation
of renal stones [5]. These researchers described this condition
as "mild hyperoxaluria." Later reports give a frequency of
"mild hyperoxaluria" in patients with stones of 12% to 63%
[5—8], 37% [9], and 50% [101. In some series, the frequency is as
low as 17% [11, 121. The scatter in these values probably results
from the use of different selection criteria (the inclusion of
patients with recurrent stones or those with single stones), from
geographic and racial differences, from different analytical
approaches, and last but not least, from differences in choosing
the cut-off point that defines "mild hyperoxaluria,"
The issue of the upper limit of normal for urinary oxalate is an
important one. Some investigators have defined mild hyperox-
aluria as a urinary oxalate excretion more than two standard
deviations above the mean, yet two considerations raise doubt
about this definition. First, the physico-chemical properties of
oxalate (which I will discuss later) are such that even small
increments in urinary oxalate might result in quite important
effects on the saturation of calcium oxalate because the effect of
raising oxalate concentration on saturation of oxalate in the
urine is linear [3]. Second, if one takes into account the
cumulative frequency plots for oxaluria given by Larsson and
Tiselius [3] and calculates similar plots from the data of Rob-
ertson et al [81, the interval between 1 and 2 SD includes far
more stone formers than normal controls. The ideal approach
should have been the receiver operating characteristic (ROC)
curve, that is, the analysis of the curve obtained plotting the
positive versus false-positive rate for selected values of ox-
aluria, which, to my knowledge, has never been attempted.
These considerations lead me to speculate that hyperoxaluria
might be etiologically as important in renal stone disease as is
hypercalciuria. What I will try to establish next is the role of
oxalate as a stone promoter, and the mechanisms of hyperox-
aluria.
Oxalate as a stone promoter
Oxalic acid, a strong organic acid, forms an insoluble salt
with calcium at physiologic pH. The clinical importance of
oxalate in renal stone disease is related to the insolubility of the
calcium oxalate salt. Because not more than 50 micromoles of
oxalate can be dissolved in one liter of water, the concentration
of oxalate in the urine must be considered a strong promoter of
calcium oxalate precipitation.
Several studies have evaluated the importance of urinary
oxalate as a determinant of calcium oxalate precipitation. In
1978, Robertson and coworkers analyzed the frequency distri-
bution of some urine constituents in a group of recurrent stone
formers and found that oxalate was a more important risk factor
in making stones than was calcium [8]. In a later study,
Robertson and Peacock demonstrated a relationship between
oxaluria and the number of stone episodes per year as well as
quantity and size of crystalluria, a relationship that was lost
when calcium was considered by itself [5]. The importance of
oxalate in the urinary saturation of calcium oxalate also was
studied by Finlayson [13]. Utilizing a mathematical approach
that takes into account the possibility that oxalate makes
complexes with other urinary ions, Finlayson found that
changes in urinary oxalate concentrations are 15 times as potent
as equimolar changes in calcium concentration in effecting
calcium oxalate saturation.
An increase in urinary oxalate can derive from: (1) increased
dietary intake; (2) increased metabolic production; (3) aug-
mented intestinal absorption; and (4) a renal leak. I will now
consider these possibilities in detail.
Oxalate is a common component of foods, but the oxalate
content of most foods is low (less than 0.01 mmol/liter).
Nonetheless, some foods (spinach, rhubarb, tea, beer, choco-
late, peanuts) are rich in oxalate; as a consequence, their
ingestion might induce hyperoxaluria. Finch et a! examined the
urine at 37° and 4°C for crystals in groups of normal subjects
eating a low'oxalate diet, an unrestricted diet, and a low-oxalate
diet with the addition of oxalate-rich foods [14]. They found no
oxalate crystals in the urine in the first two groups, whereas
10% of subjects supplemented with oxalate-rich foods showed
oxalate crystals at 37°, and 40% had crystals at 4°C. Robertson
found that calcium oxalate stone formers ingest slightly but
significantly more oxalate than do controls [151. He concluded
that this dietary factor cannot play a major role in the causation
of the "mild hyperoxaluria" because urinary oxalate does not
increase until ingested oxalate exceeds an intake of approxi-
mately 2 mmol/day. Griffith et al, in a case-control study, were
unable to find any significant difference in dietary oxalate intake
between hyperoxaluric stone formers and controls [16]. Barker
and colleagues examined the relationship between diet and
renal stones in 72 areas of England and Wales and did not find
any relationship between diet and stone formation [171. Thus,
available data fail to support a role for increased dietary intake
of oxalate as the main cause of hyperoxaluria.
Could increased oxalate excretion in patients with calcium
oxalate nephrolithiasis derive from an exaggerated dietary intake
of oxálate precursors? The two most important precursors of
oxalate are ascorbic and glyoxylic acids. Ascorbic acid accounts
for 35% to 50% of the daily urinary excretion of oxalate [18], but
its metabolic turnover is limited, so the small quantity commonly
ingested with foods cannot result in increased oxalate synthesis
[19]. Even the impact of megadoses of vitamin C on oxalate
production is far from established. Major points of confusion are
the methods used to assay oxalate, the fact that ascorbate is
unstable at room temperature and at physiologic pH in the urine,
and that it undergoes a nonenzymatic oxidation to oxalate [201.
The consequence of high ascorbate intake on urinary oxalate
recently was readdressed by Liedtke et al, who assayed urinary
oxalate by the oxalate-oxidase method together with two ion
chromatographic methods in 10 normal volunteers before and
after ingestion of 2 g of vitamin C per day [21]. When fresh urines
were analyzed, they found no difference in urinary oxalate excre-
tion from control.
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Thus a reasonable conclusion seems to be that the dietary
intake of ascorbic acid has little or no effect on the levels of
urinary oxalate in normal subjects. The only exception to this
conclusion is the study by Briggs, who administered a short
course of ascorbic acid (4 g/day) to 2 healthy men [221. The
ascorbic acid promoted an extremely large increase in oxalate
excretion. The family members of one of these subjects also
were investigated, and the same reaction to vitamin C occurred
in the father. This observation raises the possibility that rather
than an augmented intake, a derangement in ascorbate metab-
olism might lead to hyperoxaluria. The possibility that an
abnormality in ascorbate metabolism might result in hyperox-
aluria in recurrent stone formers was investigated by Chalmers
et al [23]. They studied 17 stone formers and 11 controls and
found that stone formers excreted significantly more oxalate
and less ascorbate than did controls. They also loaded 5
patients with ascorbate either by mouth (4 g) or intravenously
(500 mg) and demonstrated a larger and more delayed oxalate
excretion only after ingestion of ascorbate. The authors con-
cluded that malabsorption of ascorbate might lead to an in-
creased conversion of ascorbate to oxalate in the gut. In a later
study, Cowley et a! compared the uptake of citrate and ascor-
bate from the gut into the blood, presented evidence of impaired
absorption of hydroxycarboxylic acids in stone formers, and
suggested a defect in a common carrier that absorbs both
ascorbate and citrate from the gut [24]. These studies leave
open the question of a possible causal role of vitamin C intake
in promoting hyperoxaluria but suggest that excessive intake of
citrate might be a promoter of stone formation [251.
The other important precursor of oxalate, glyoxylate, ac-
counts for 50% to 70% of urinary oxalate [26]. The major
sources of glyoxylic acid in humans are glycine, glycolic acid,
and serine. Hydroxyproline also can be reversibly converted to
glyoxylic acid by a vitamin B6-dependent step. Other possible
minor precursors of oxalate include gelatin, tryptophan, phen-
ylalanine, tyrosine, threonine, aspartic acid, creatinine, and
purines [27]. The possibility that an increased dietary intake of
all these substances can cause hyperoxaluria raises the possi-
bility, discussed in a recent Nephrology Forum presentation
[28], that protein intake is a predisposing factor to stone
formation. To summarize, it seems unlikely that an increased
intake of oxalate or its precursors is responsible for stone
formation. Equally unlikely seems the chance of a derangement
in endogenous oxalate synthesis. In fact, the indisputable
demonstration that hyperoxaluria in stone formers disappears
during fasting argues against the possibility of a primary disor-
der in oxalate metabolism [7, 29].
Does increased intestinal absorption of oxalate cause its
appearance in large amounts in the urine? This issue was first
addressed by Hodgkinson, who showed an increased oxalate-
to-creatinine ratio in the urine of 98 stone formers in compari-
son with 67 normal controls [7]. Further, he showed that this
difference disappeared after fasting. Because the dietary intake
was the same in both groups, he concluded that stone formers
had a higher intestinal absorption of oxalate. Using '4C oxalate
as a tracer, Marangella et al found a mild increase in intestinal
absorption of oxalate in patients with calcium oxalate nephro-
lithiasis [301, which was more evident when the hypercalciuric
stone formers' group was considered. However, applying the
same technique as Marangella et al, Tiselius and colleagues
found no significant difference between stone formers and
controls [31]. Manoharan and coworkers, revisiting the problem
of "mild hyperoxaluria" in renal stone disease, have confirmed
a higher-than-normal urinary excretion of oxalate in stone
formers that disappeared after fasting [29]; this finding confirms
the observation by Hodgkinson [7]. Although the data conflict,
some of these studies do suggest the possibility of an increased
intestinal absorption of oxalate in calcium oxalate nephrolithi-
asis.
Finally, a renal leak might produce hyperoxaluria. To prop-
erly assess the possibility of a renal leak of oxalate, an accurate
measurement of plasma oxalate is indispensable. Until recently,
accurate measures of plasma oxalate were unavailable. In two
recent studies, however, both plasma and urinary oxalate were
assayed by highly accurate methods [29, 32]. In both studies,
stone formers appeared to secrete more oxalate in the renal
tubule. This increased excretion occurred despite plasma levels
of oxalate that were the same or even less than those in
controls. These observations support the view that a renal leak
of oxalate due to a tubular handling defect is present in patients
with calcium oxalate nephrolithiasis, or at least in a subgroup of
these patients. Further comparable studies are required to
confirm this hypothesis and establish its quantitative impor-
tance.
Defective cellular oxalate transport
Is a defect in cellular oxalate transport the fundamental
abnormality in calcium oxalate nephro!ithiasis? The common
finding of mild hyperoxaluria, most probably resulting from
increased intestinal oxalate absorption, exaggerated renal ox-
alate loss, or both, in calcium oxalate stone formers raises the
possibility that defective cellular oxalate transport is the basic
abnormality of the disease. However, adducing sufficient evi-
dence for this hypothesis in humans is extremely difficult. In
principle, abnormalities in oxalate handling should reside both
in the gut and in the kidney, but cells from these locations
cannot be investigated directly. Furthermore, no experimental
model of inherited calcium oxalate stone disease exists. For
these reasons, any examination of this problem must focus on
cells not as directly involved in oxalate transport as those in the
intestine and kidney. Such an indirect approach to the study of
abnormalities in membrane ion transport is not new; it has been
applied, for example, in the field of hypertension, in which the
investigation of circulating cells such as platelets, red blood
cells, and leukocytes has suggested the possibility of an abnor-
mality in membrane transport in vascular smooth muscle cells.
Our search for a cell model suitable for the study of oxalate
transport focused on the red blood cell. In 1975 Aubert and
Motais demonstrated that the red blood cell is permeable to
organic acids and that its transport of dicarboxylic acids was
carrier-mediated [33]. In a later paper, mainly aimed at clarify-
ing the mechanism by which sulfonamides inhibited anion
transport, Cousin and Motais evaluated the organic anion
permeability of red blood cells by studying the steady-state self
exchange of oxalate [341. The assay system we employed to
evaluate red blood cell steady-state oxalate self exchange is
derived from that described by Cousin and Motais [34].
In our first study on red blood cell oxalate self exchange in 28
"idiopathic" renal stone formers, we found a higher-than-
normal exchange rate in 78% of patients [35]. This fraction was
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confirmed in a later study, which examined 98 patients [361. To
date we have examined a total of 217 renal stone formers, and
the abnormality in red blood cell oxalate self exchange has been
present in 68% (Fig. 1). However, this group is heterogeneous
because it also includes those who had only single stones.
Because family studies indicated an appreciable genetic con-
tribution to the risk of having urolithiasis, we attempted to
assess whether the abnormality in oxalate transport was genet-
ically determined. We studied five families in which the abnor-
mality in oxalate transport was detectable in one or more
members and concluded that the abnormal red blood cell
oxalate self exchange follows the pattern of an autosomal,
monogenic, dominant trait with complete penetrance and vari-
able expressivity [36]. These data led us to surmise that a
genetically transmitted cellular abnormality in oxalate transport
might be associated with calcium oxalate renal stone disease.
Interestingly, the transmission of two other conditions associ-
ated with renal stone disease, that is, familial hypercalciuria
[37] and renal tubular acidosis [381, also has been considered an
autosomal dominant trait. Although environmental factors con-
found interpretation, a substantial genetic component in neph-
rolithiasis is possible [39—45]. The model that fits best is
multifactorial, and a defect in cellular oxalate transport might
be one such factor.
In the search for a closer link between the red blood cell
2 3
abnormality and stone formation, we looked for a possible
relationship between the oxalate exchange rate and the 24-hour
urinary oxalate excretion, but we were unable to demonstrate
one, even with large numbers of patients (Fig. 2). However, for
a calcium oxalate stone to form, oversaturation need not be
continuous; some peaks during the day should be sufficient.
Indeed, in oxalate tolerance tests carried out in pairs of brothers
living together and eating the same diet, a significant increase in
urinary oxalate could be demonstrated at 2 and 4 hours after the
load in brothers with abnormal red blood cell oxalate transport
when compared with their siblings with normal red blood cell
oxalate transport [36]. Thus, peaks of urinary oversaturation
consequent to more rapid absorption and excretion of dietary
oxalate remain possible.
Oxalate transport via band 3 protein. In an attempt to clarify
the red blood cell abnormality, we wanted to be sure that the
abnormality was intrinsic to the cell. To this end, we incubated
red blood cells with high steady-state oxalate self exchange with
normal plasma and normal red blood cells with plasma of
patients whose red blood cells showed an increased oxalate self
exchange; we found that these maneuvers did not significantly
modify the initial exchange rate (Fig. 3).
Given the results of Cousin and Motais' experiment [341, we
suspected the anion transporter, band 3 protein, as the culprit of
the cellular abnormality, since these authors had suggested a
competition between oxalate and chloride/bicarbonate move-
ments. Knowing that disulfonic stilbenes react almost exclu-
sively (more than 95%) with band 3 in erythrocytes [46, 47], we
treated red blood cells with high transmembrane oxalate fluxes
with 5,5'-dithiobis (-2 nitrobenzoic acid) (DTNB) and 4,4'-
diisothiocyano-2,2'-stilbene-disulfonic acid (DIDS) and found
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Fig. 2. Scattergram showing the relationship between steady-state
oxalate self exchange (K) in red blood cells and 24-hour urinary
oxalate. (For details see Ref. 36).
Fig. 1. Scattergram showing the '4C oxalate flux rate (K) in 217
idiopathic calcium oxalate stone formers. The dotted line denotes the
upper limit of normal (see Ref. 36).
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Fig. 3. A typical cross-incubation experiment is depicted. Red blood
cells from stone formers were incubated with compatible plasma from
normal subjects and vice versa. Thereafter '4C oxalate self-exchanges
were determined. The ordinate depicts the transformation of '4C
oxalate concentrations in the incubation medium (A) at defined time (T)
(see Ref. 36).
that these agents not only corrected the high oxalate self
exchange, but almost abolished it [48]. We interpreted this
experiment as evidence of a true movement of oxalate through
the cell membrane occurring via band 3 protein.
It may be useful to recall here some properties of the band 3
protein, which recently has been cloned [49, 50]; the corre-
sponding gene is located on chromosome 17. Band 3 is a 911
amino acid protein. Similar in structure to other anion exchang-
ers, it is divided into 3 regions: a hydrophilic cytoplasmic
domain (residues 1-403), which interacts with a variety of
membrane and cytoplasmic proteins; a hydrophobic transmem-
brane domain (residues 404-882), which constitutes the anion
transporter and controls the rapid electroneutral sequential
exchange of chloride with bicarbonate; and an acidic C-terminal
residue (residues 883-911) of unknown function (Fig. 4). The
entire transmembrane portion of the molecule seems to be
necessary for anion exchange. Amino acids that might be
involved in anion exchanges include lysine, arginine, histidine,
and glutamic acid. Although both intracellular and extracellular
arginine are important in the anion exchange [51], possibly
serving as a critical binding site, proximal and distal lysines in
or near the external opening of the channel are covalently
bound by the specific anion transport inhibitor DIDS [52].
Finally, extracellular arginine and glutamate residues near the
DIDS binding site seem to be necessary for anion transport [53,
54].
What makes band 3 protein transport anions? One possibility
that immediately comes to mind is that band 3 controls anion
transport by phosphorylation or dephosphorylation. Indeed,
many red blood cell proteins are phosphorylated, and many
membrane and cytosolic protein kinases and several phos-
phoprotein phosphatases are found in these cells. Human red
blood cells contain two casein kinases, one membrane bound
(type 1) and one in the cytosol (type 2); two cAMP-dependent
kinases, again, one in the membrane (type 1), and one in the
cytosol (type 2); a phospholipid-dependent protein kinase C; a
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Fig. 4. Schematic description of band 3 protein in red blood cell, freely
derivedfrom Alper et al [941. The anion transporter is constituted by the
hydrophobic transmembrane domain, residues 403-882.
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Fig. 5. A typical experiment after A TP depletion is described. Full
symbols are the control values of the '4C oxalate self exchange in red
blood cells from a stone former. Empty symbols refer to the same red
blood cells depleted of ATP by incubation with 5 mM iodoacetamide
and 5 mM inosine for 90 minutes at 37°C. (For a better understanding
see also Ref. 59).
calcium-calmodulin-dependent kinase; a membrane-bound ty-
rosine kinase; and at least two more protein kinases that
copurify respectively with protein 4,1 and 4.9 [55].
For phosphorylation to occur, the first step is the transfer of
a phosphate group of the donor ATP to an acceptor. We
reasOned that if phosphorylation is important, reducing ATP in
the cell should result in a decrease of oxalate exchange. In fact,
when we promoted red blood cell ATP depletion with iodoac-
etamide, oxalate self exchange was almost abolished (Fig. 5).
We also performed parallel experiments in which the kinetics of
band 3 phosphorylation were examined at different times after
energy depletion (8, 16, 24 hours) and following the addition of
glucose and adenine to the incubation medium (4, 8, 16 hours).
We saw a progressive decrease of band-3 phosphorylation, with
an 85% recovery of the initial casein phosphorylation and a
definite loss of tyrosine phosphorylation (unpublished observa-
tions). The assay of casein and tyrosine activities against
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exogenous substrates confirmed the loss of activity of the latter
enzymes. Furthermore, because DIDS exerts an effect on
oxalate self exchange, we investigated the effect of DIDS (50
jimol/red blood cell hematocrit of 25% for 30 mm at 30°C) on the
band-3 phosphorylation rate. We found a 35% inhibition; mem-
brane casein and tyrosine kinase activities against exogenous
substrates did not change (unpublished observations). These
expriments suggest that the addition of DIDS promotes some
modifications in the protein that either interfere with phosphor-
ylation of the intramembrane domain or are transmitted to the
intracellular domain, where most phosphorylation occurs [561.
As a whole, these experiments suggest a link between anion
transport capability and the state of phosphorylation of band 3.
The observation that thiazides and amiloride (which decrease
the exchange of oxalate) induce similar changes in the phos-
phorylation rate of red blood cell membrane is in keeping with
such an interpretation [57, 58].
Indeed, studies of the endogenous phosphorylation of red
blood cell ghosts from stone formers with faster-than-normal
oxalate self exchange revealed that the time-course profiles of
protein 32P labeling exhibited a high phosphorylation both of
band 2 and band 3 in comparison with normal controls [591. The
increased phosphorylation rate of band 3 observed in stone
formers might be explained by an alteration in the conforma-
tional structure or by a topologic rearrangement in the membrane
leading to the exposure of additional sites for phosphorylation,
by an imbalance between protein kinase and phosphatase
activities, or by an excess of activators or a defect of inhibitors
of both enzymes. The first possibility seems to be ruled out by
the demonstration of an increased phosphorylation not only of
red blood cell band 3, but also of band 2 proteins. It is, in fact,
difficult to support a defect in structure or arrangement of two
proteins simultaneously.
In investigating the remaining possibilities, we looked for one
or more substances known to be altered in nephrolithiasis, but
ones capable of interacting with protein kinase or protein
phosphatase. Glycosaminoglycans (GAGs), we thought, were
the best candidates.
Glycosaminoglycans are important in nephrolithiasis owing
to their ability to oppose calcium oxalate crystallization in vitro
[60—65]. To determine whether they have a similar action in
vivo, researchers have repeatedly assayed GAGs in stone
formers. Although researchers are not unanimous [66-69], the
consensus points to decreased urinary excretion of GAGs in
patients with renal stone disease [8, 70—75]. In nephrolithiasis,
there is not only a quantitative defect, but also a qualitative one,
because in stone formers the degree of sulfation of GAGs is
higher than normal [68, 761. Interestingly, the defect in GAG
synthesis in patients with renal stone disease does not seem to
be limited to the urinary tract; decreased production of GAGs
by cultured skin fibroblasts also has been described [77]. On the
other hand, GAGs are known to be potent inhibitors of many
protein kinases, such as casein kinase [78—801, tyrosine kinase
[811, and phospholipid-sensitive calcium-dependent protein ki-
nase [821.
To assess the potential role of GAGs in determining the
abnormality in steady-state oxalate self exchange, we carried
out some preliminary studies on red blood cells in vitro, and
tested the effect of low-molecular-weight heparin, dermatan
sulfate, heparan sulfate, and chondroitin sulfate A and C on
both oxalate self exchange and band-3 phosphorylation. All the
substances showed an inhibition of both oxalate self exchange
and band-3 phosphorylation, with the following order of mag-
nitude: low-molecular-weight heparin > dermatan sulfate >
heparan sulfate> chondroitin sulfate A > chondroitin sulfate C
[83].
Next we assessed the effect of these agents in vivo. To this
end we evaluated GAG content, oxalate self exchange, and
band-3 phosphorylation rate in a group of idiopathic calcium
oxalate stone formers. The erythrocyte GAG content of stone
formers was lower than that in controls and, as expected,
oxalate self exchange and band-3 phosphorylation rates were
higher. Furthermore, oxalate exchange and phosphorylation
correlated inversely with GAG content [841.
According to these data, the following hypothesis seems
likely in our opinion: a reduced GAG content decreases the
inhibition of the protein kinase(s) devoted to band-3 phosphor-
ylation and leads to faster transmembrane oxalate transport.
What remains to be done is an analysis of the possibility that
intestinal absorption and renal secretion of oxalate occur in a
similar fashion to that in red blood cells, that is, via band 3 or
band-3-related proteins. Only if the answer is positive can a
cause-and-effect relationship between the red blood cell abnor-
mality and the pathophysiology of renal stone disease be
confirmed.
Oxalate transport by the gut and localization of band-3-like
protein along the gastrointestinal tract. Studies in vitro support
the theoretical possibility that oxalate can be absorbed through-
out the intestine [85]. In vivo, however, oxalate uptake occurs
within one to 8 hours after ingestion; thus, in normal subjects
the proximal portion of the small bowel acts as a major
absorptive site [86]. Most of the dietary oxalate is thought to be
bound by intraluminal calcium in the small intestine and is
subsequently excreted as insoluble calcium oxalate salts. This
view assigns to intraluminal calcium ion concentration a pivotal
role in determining the amount of ingested oxalate absorbed and
depicts an inverse relationship between the quantity of ingested
calcium and the amount of reabsorbed oxalate. According to
Prenen et al [86], however, no difference exists in the absorp-
tion kinetics of soluble oxalate and calcium oxalate.
Oxalate absorption by the gut has been considered for a long
time to be a passive, non-energy-dependent process [85, 871. A
net transport of oxalate was subsequently demonstrated in the
rat colon, however [88]. Furthermore, in the rat colon mucosa,
the addition of disulfonic stilbenes inhibited both oxalate and
chloride fluxes, and acetazolamide significantly reduced the
mucosal to serosal movements of both ions [88]. These findings
suggested that oxalate and chloride share a common transport
pathway, and that chloride exchanges with bicarbonate. These
studies enable us to conclude, at least as far as the rat colon is
concerned, that an energy-dependent net oxalate absorption
occurs that is sensitive to anion transport inhibitors and that
parallels chloride movements. Disulfonic-stilbene-sensitive
chloride/bicarbonate exchangers also have been demonstrated
in duodenum and jejunum [89—92]. Is there any evidence of the
presence of band 3 or band-3-related proteins along the gastro-
intestinal tract? Polyclonal antibodies to purified mouse red
blood cell band 3 protein bind to plasma membranes of gastric
oxyntic cells [93]. Competitive studies revealed that the epitope
shared between gastric antigen and red blood cell band 3 was
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restricted to the -COOH terminal domain of the protein, which
is known to contain the catalytic site for anion exchanges [93].
Alper et al, using Northern blot hybridization with mRNA from
many murine epithelial cells, showed that a probe encoding a
stretch of the red blood cell band 3 membrane spanning domain
detected, under low stringency conditions, an mRNA from
colon [941. Another attempt at identifying and characterizing
cDNAs encoding band-3-related proteins and determining their
mRNA distribution in the gut has been made in the rat [95]. Two
proteins related to the intramembranous domain of band 3 were
isolated. Northern blot hybridization analysis disclosed an
mRNA of apparently 4.4 kb in the stomach as well as in the
small and large intestines. In the rat duodenal brush-border-
membrane vesicles, chloride/bicarbonate exchange was stimu-
lated by cAMP and was inhibited by specific cAMP-dependent
protein kinase inhibitors [96]. These findings suggest that acti-
vation of the exchange requires a cAMP-dependent protein
kinase with phosphorylation of some element of the transport
pathway. Evidence for protein kinase C as a regulator of
intestinal electrolyte transport also has been presented. In fact,
protein kinese C promotes the phosphorylation of specific
proteins of microvillous membrane of enterocytes [971, and its
activators, phorbol ester and diacylglycerol, stimulate electro-
genic anion secretion in intestine [98].
In sum, current evidence suggests the possibility of active
oxalate uptake by the small intestine, which occurs through a
chloride/bicarbonate exchanger and which is inhibited by di-
sulfonic stilbenes. Evidence also indicates that band-3-related
proteins are present along the gastrointestinal tract; these
proteins, although not encoded by the same gene as red blood
cell band 3 protein, are likely the product of very similar genes.
Furthermore, it is likely that the transporter must be phosphor-
ylated to be active.
Renal handling of oxalate and localization of band-3-like
protein along the nephron. Many transport systems that display
some functional similarities with red blood cell band 3 protein
are expressed in urinary epithelia. If we posit a transport
system as band 3 related according to an anion-exchange
mechanism or to stilbene disulfonate sensitivity, we could
conclude that band-3-related anion transporters exist all along
the renal tubule [94]. Following an immunologic approach and
employing antibodies raised against red blood cell band 3,
immunoreactivity was detected in a variety of cell types [99,
1001. However, the antisera initially used were not very specific
[101, 1021 and probably recognized only epitopes restricted to
the cytoplasmic domain of band 3, which is not involved in
anion transport. Subsequent studies with more purified antibod-
ies, or monoclonal antibodies raised against the intramembra-
nous domain of band 3, have shown specific fluorescence only
along the basolateral membrane of alpha intercalated cells of
the collecting duct [103—106]. The application of molecular
biologic techniques has enabled this field to take a big step
forward. Red blood cell band 3 from many species has been
cloned [49, 50, 94, 107—1091, as has kidney band 3 from humans
and experimental animals [110—112]. It appears from these
studies that red blood cell band 3 differs little from kidney band
3, except for the intracytoplasmic domain, which is truncated in
the renal protein. At the moment, a protein encoded by the
same gene as red blood cell band 3 appears to exist only in the
basolateral membrane of alpha intercalated cells of the collect-
ing duct of the kidney.
Oxalate is freely filtered by the glomerulus, as suggested by
the absence of protein binding of '4C oxalate. Micropuncture
techniques have been widely applied in the study of oxalate
concentration along the nephron. Endogenous filtrate collec-
tions in the proximal convoluted tubule have shown high
oxalate concentrations in the tubular fluid as compared with
inulin; these findings indicate a net tubular secretion of oxalate
[113—115]. Net tubular secretion of oxalate in this nephron
segment has been confirmed in isolated and perfused rabbit
renal tubules [1161. In distal tubule and final urines, the oxalate-
to-creatinine ratio was very close to that of the proximal tubule,
excluding net secretion of oxalate beyond the proximal convo-
lution [113—115]. The fractional excretion of oxalate in the final
urines was between 1.09 and 1.28, meaning that approximately
10% to 30% of urinary oxalate in normal conditions derives
from net tubular secretion.
Active secretion of organic anions in the proximal tubule
requires uptake from the contraluminal site across the mem-
brane into the cell and luminal secretion through the brush-
border membrane. As far as proximal tubule contraluminal
anion transport is concerned, three main systems have been
characterized: (1) an exchange system for sulfate and oxalate,
(2) a cotransport system for sodium and dicarboxylates, and (3)
an exchange system for hydrophobic anions and long-chain
fatty acids [117, 118]. This list might be extended to five given
the evidence that urate and PAH are transported on a separate
exchanger, and that a stilbene-sensitive, sodium-independent
chloride/bicarbonate exchanger also has been identified [1191.
Oxalate transport occurs only through the sulfate, oxalate,
bicarbonate exchanger [1 17, 118], which shares in common with
the red blood cell anion exchanger the ability to transport both
sulfate and oxalate, and to be inhibited by the same compounds,
such as disulfonic stilbenes, which inhibit red blood cell band 3
protein [120, 1211. To create a driving force for sulfate exit via
the contraluminal membrane, sulfate must first accumulate in
the cell. This happens by virtue of sodium-coupled sulfate
transport in the luminal membrane. Because the first step in
oxalate secretion is an exchange with sulfate at the contralumi-
nal cell side, this exchange is indirectly driven via the sodium-
sulfate cotransport system in the luminal membrane.
How can oxalate leave the cell to be secreted into the tubular
lumen? In the rabbit renal microvillus membrane, a chloride
(formate)/oxalate exchanger has been described [122]. The
exchange is electrogenic, pointing to the movement of one
monovalent anion (chloride or formate) in exchange for a
divalent anion (oxalate), and it is inhibited by DIDS and, to a
lesser extent, by furosemide. A hypothetical way for oxalate to
cross the tubular cell can now be outlined (Fig. 6). Oxalate is
taken up from blood at the contraluminal side in exchange with
sulfate, and it enters the luminal fluid in exchange with chloride.
Sulfate, in turn, enters the cell with sodium.
As we look for a link between the abnormality found in red
blood cells and a possible renal leak of oxalate, we cannot
neglect two certainties: (1) an anion transporter encoded by the
same gene as band 3 is located in the basolateral membrane of
the alpha intercalated cell of the collecting tubule, but it does
not transport oxalate; and (2) the proximal tubular cell contains
at least two anion transporters involved in transcellular oxalate
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movements that share with band 3 protein all its functional
properties but are structurally different from it.
Let us consider point one first. Alpha intercalated cells are
proton-secreting cells in which a fall in intracellular pH is
thought to switch on a hydrogen translocating ATPase inserted
in the luminal membrane. The hydroxide formed as a result of
the proton extrusion reacts with carbon dioxide to form bicar-
bonate in a reaction catalyzed by carbonic anhydrase. The
generated bicarbonate then leaves the cell via the basolateral
membrane anion transporter in exchange with chloride, which
leaves the cell through a chloride channel [123]. An indirect
attempt at establishing the relative importance of the sodium!
hydrogen antiporter and the chloride/bicarbonate transporter in
regulating intracellular pH has been made in LLC-PK1 cells
[124]. When stimulated by an acid load of about 0.3 pH unit, the
chloride/bicarbonate exchanger could mediate acid-base fluxes
greater than those mediated by the sodium!hydrogen ex-
changer.
If such a mechanism is in place, and a basolateral anion
exchanger works at a higher than normal rate, the result could
be an increased secretion of hydrogen with a consequential fall
in urinary pH. Do we have proof that urinary pH is lower in
patients who form pure calcium oxalate stones? The answer is
yes. Robertson et al reported data on urinary pH in normal
subjects and calcium oxalate stone formers in the United
Kingdom, Saudi Arabia, and United Arab Emirates; in all three
countries, urinary pH was lower in the calcium oxalate stone
formers [125].
Let us now recall what occurs in red blood cells, where the
abnormality seems to be related to a defect in the phosphory-
lation of band 3, and which probably occurs not so much
because of a structural defect of the protein, but rather because
of an excess of activity of the specific protein kinase(s). The
next logical question is whether there is any evidence of
phosphorylation of alpha intercalated cell band-3-like protein.
Indeed, some indirect evidence does exist. Proton secretion by
rabbit medullary collecting duct is stimulated by cAMP ana-
logues and prostaglandin E2 [1261. It is reasonable to suspect
that at least the action of cAMP requires protein phosphoryla-
tion, but the fact that band-3-like protein is the specific sub-
strate of this supposed phosphorylation is still open to doubt. In
fact, the chloride that enters the cell in exchange with bicar-
bonate must exit via a specific chloride channel, and diphenyl-
amine-2-carboxylate, which is a specific chloride channel
blocker [127], can stop chloride/bicarbonate exchange [1281.
Because cAMP activates chloride channels [129], the increase
in chloride/bicarbonate exchange could be secondary to an
increased chloride conductance. A direct effect of diphenyl-
amine-2-carboxylate on the chloride/bicarbonate exchanger
also has been reported, however [128].
To summarize, evidence exists of an exchanger encoded by
the same gene as band 3 protein in the basolateral membrane of
collecting duct proton-secreting cells, probably requiring phos-
phorylation for its activation; and, calcium oxalate renal stone
formers have a lower-than-normal urinary pH. One could
conclude that, leaving the oxalate aside, a link between the red
blood cell abnormality and renal stone formation might be
related to the formation of more acidic urines, in which the
precipitation of calcium oxalate salts is facilitated.
Now let us return to the proximal tubule, the site of oxalate
secretion. We know that here at least two transporters are
involved in oxalate movement. These transporters share almost
all the functional properties of red blood cell band 3 protein but,
despite functional similarities, are not the same molecule as
band 3. It is appropriate to ask this question: are these anion
exchangers encoded by genes closely related to the one of band
3? In human genomes, band 3 is encoded by a single-copy
nuclear gene, the expression of which is limited to erythroid
cells and to alpha intercalated cells of the collecting duct of the
kidney. However, the observation of homologous transcripts
and the identification of immunologic cross-reacting peptides in
many non-erythroid cells raises the possibility that anion ex-
change in non-erythroid cells might be mediated by closely
related molecules. It is true that, using Northern blots of mouse
kidney poly (A) selected RNA under high stringency condi-
tions, a probe encoding a stretch of the red blood cell band 3
membrane spanning domain detects only a 4.2 kb transcript.
But under low stringency conditions, two major renal mRNAs
and four minor species can be identified [94]. The mRNA
transcripts were identified by probes from the domain of band 3
performing the anion exchange, so it is possible that these
transcripts encode proteins functionally similar to the chloride/
bicarbonate exchanger of red blood cells. In keeping with such
a possibility is the demonstration that a monoclonal antibody
against the membrane domain of band 3 protein binds to a 43 kD
protein with an amino acid composition very similar to red
blood cell band 3 localized in rabbit renal tubular brush-border
membrane [130]. Furthermore, complementary DNAs encoding
two proteins related to red blood cell band 3 have been isolated
from rat stomach, brain, and kidney [951. These proteins exhibit
an amino acid homology to band 3 of 50% and 52%, respec-
Brush-border
membrane
Proximal tubule
Basolateral
membrane
Sulfate
HC03
oxalate
Fig. 6. Schematic depiction of the supposed mechanism of oxalate
secretion by the proximal renal tubule. Oxalate enters the cell across
the basolateral membrane in exchange for sulfate and leaves the cell
across the brush-border membrane in exchange for chloride. Sulfate, in
turn, enters the cell across the brush-border membrane with sodium.
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tively. Interestingly, the C-terminal hydrophobic region of
these proteins has a higher amino acid homology with the anion
exchanger (64% and 69%, respectively), and very similar hy-
dropathic profile, suggesting the same transmembrane organi-
zation.
Although the problem of the structural similarities as well as
that of the genetic control of true band 3 and band-3-like
proteins is far from being resolved, these studies raise the
possibility that if something is wrong in red blood cell band 3,
the same might be true in other anion exchangers, like those
devoted to oxalate transport in the proximal tubule.
What I have reviewed until now establishes only the reason-
ableness of a causal connection between the red blood cell
abnormality and defective handling of oxalate by the kidney and
the gut. We recently tried to confirm the validity of this
hypothesis with an experiment that must be considered prelim-
inary. We reasoned that if we could correct the red blood cell
abnormality, we could lower oxalate excretion. To this end, we
treated a group of stone formers with a mixture of GAGs (70%
low-molecular-weight heparin, and 30% dermatan sulfate). We
know from previous pharmacokinetic studies that 55% of an
administered dose is absorbed and 25% is excreted unmodified
in the urine. A 15-day treatment yielded a fall in both red blood
cell oxalate self exchange and band-3 phosphorylation, but
more important was our observation that these modifications in
red blood cells were paralleled by a significant decrease in
urinary oxalate excretion [131]. Furthermore, the '4C oxalate-
to-creatinine ratio was changed from 1 .4 before treatment to 1.2
after treatment, meaning that oxalate handling was affected
similarly in red blood cells and renal tubular cells.
This is not a definitive answer, but it does foresee a promising
future, Although much work is still to be done, the availability
of molecular genetic techniques surely enables us to clarify the
molecular structure of oxalate transporter(s) and the mecha-
nism(s) by which their activity is controlled. We don't know
whether anion exchangers other than band 3 require phosphor-
ylation for activation. However, the chance to examine this
possibility is not far away. In fact, an anion transport has been
induced in oocytes of Xenopus laevis by expression of a mouse
erythroid band 3 protein encoding a cRNA [132]. It is reason-
able to predict the induction in the same way of other band-3-
like proteins; it then might be possible to control the mecha-
nisms that initiate the exchange.
Questions and answers
DR. GIUSEPPE ROMBOLA (Division of Nephrology, Niguarda-
Ca' Granda Hospital, Milan, Italy): With respect to the phys-
iologic function of the red blood cell band 3, one major role of
this exchanger could be the participation in the regulation of
intracellular pH (pHi). Olsnes et al recently showed that the
activity of a DIDS-inhibitable anion antiport in green monkey
and fetal hamster renal cells (a similar if not identical exchanger
as band 3) is strictly regulated by pHi [133]. High levels
stimulate the exit of bicarbonate from cells, and low levels
inhibit it [1331. Thus one might expect that increased red blood
cell oxalate self exchange in calcium stone formers either might
result from a primary disturbance of intracellular acid-base
balance (that is, intracellular alkalosis) or, alternatively, might
produce intracellular acidosis due to exaggerated base loss. We
recently presented preliminary data on pHi (using the fluores-
cent probe BCECF) in peripheral lymphocytes from hypercal-
ciuric calcium stone formers and controls [134]. Resting pHi
was not different from normal, but when the cells were exposed
to a sodium-free medium, pHi decreased further than in control
patients. We suggest that an exaggerated base loss from the
cells is a primary event that results in pHi changes only if H
exit (by Na/H antiport) has been concurrently turned off. Did
you characterize the red blood cell anion exchanger in calcium
stone formers by kinetic studies? This could enable you to
differentiate better between increased activity, that is, Vmax,
and increased affinity, that is, Km.
DR. BORSATTI: Leukocytes possess a band-3-like protein, so
your data might fit well with a primary dysfunction of this
exchanger. We did not perform kinetic studies in red blood cells
of stone formers.
DR. MAuRIzIo SURIAN (Chief, Dialysis Unit, Maggiore Hos-
pital, Lodi-Milan): What relationship might exist between the
red blood cell abnormality in oxalate self exchange and the
abnormality in calcium-magnesium ATPase described by Bian-
chi et al [135]?
DR. B0RsATTI: Calcium-magnesium ATPase activity depends
on intracellular calcium, and it is calmodulin dependent. It is
possible that the protein kinase or one of the protein kinases
associated with the phosphorylation of band 3 is calcium
dependent. Indeed, trifluoperazine, which is considered to be a
calmodulin antagonist, lowers oxalate self exchange in red
blood cells of stone formers [136]. So intracellular calcium
might be the link. We need to learn more about the one or more
factors that control oxalate handling by the proximal renal
tubular cell. I know that Drs. Cab' and Wandzilak are working
on oxalate transport by LLC-PK1 cells, and probably they can
add something more.
DR. LORENZO CAL0' (Institute of Internal Medicine, Division
of Nephrology, University of Padova, Padova): Our prelimi-
nary data show that diacylglycerol increases oxalate uptake by
LLC-PK1 cells, while the reverse happens with heparin.
DR. ANTONIA FABBRIS (Division of Nephrology, University
Hospital, Verona): Recently your group showed that sulodex-
ide, an animal extractive GAG composed of 70% low-molecu-
lar-weight heparin and 30% dermatan sulfate, modulated mem-
brane kinase activities [83, 131] and reduced oxaluria [1311. In
our experience, sulodexide increases the urinary excretion of
GAGs. Do you have any information about the mechanisms
underlying the effects of GAG on intestinal absorption or in
renal handling of oxalate?
DR. B0RSATTI: Acute intravenous administration of GAGs
lowers oxalate renal clearance, which is evidence of a direct
effect of these substances on the kidney. However, if GAGs
were only active on the kidney, they could not exert any
long-lasting effect on urinary oxalate, because the steady-state
input and output must be the same. A two-week oral treatment
with GAGs, a time interval at which a new steady state most
probably was achieved, promotes a significant fall in urinary
oxalate; thus we have indirect evidence that GAGs' effects
extend beyond the kidney. Because oxalate input to the system
relies on intestinal absorption and on endogenous production,
we presume that GAGs also must be active at one of these
steps.
DR. GIUSEPPE VEzzoLl (Division of Nephrology, San Ra-
faele University Hospital, Milan): Many cell functions are
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regulated by phosphorylation processes and many protein ki-
nases are present in cells. Among them, casein kinases phos-
phorylate band 3 and spectrin, whereas GAGs inhibit their
activity and the activity of other protein kinases. So it is
possible that GAG reduction could affect some enzyme func-
tions or the cytoskeleton organization in calcium oxalate stone
formers. Do you have evidence for or against this hypothesis?
DR. BORSATTI: The cytoplasmic domain of red blood cell
band 3 protein binds ankyrin, band 4.1 and 4.2 proteins,
glycolytic enzymes, and hemoglobin. Furthermore, the red
blood cell band 3 cytoplasmic domain is actively phosphory-
lated by several kinases, including a tyrosine kinase, a cAMP-
independent kinase, a protein kinase C, and a calcium-stimu-
lated protein kinase. The binding site for glycolytic enzymes
and hemoglobin is lost in non-erythroid band-3-like protein,
whereas that for ankyrin is preserved. In fact, band-3-like
protein has been found co-localized with an immunoreactive
form of ankyrin and spectrin in the basolateral membranes of
collecting duct intercalated cells [103]. I would not be surprised
to find that a malfunction in the cytoskeleton organization of
cells responsible for oxalate metabolism exists. The problem is
how to identify such a defect. As far as the erythrocyte is
concerned, we have not looked for abnormalities in glycolytic
enzymes or in cytoskeleton organization.
DR. VJNCENZO CALDERARO (Institute of Internal Medicine
and Nephrology, Federico II University, Napoli): I think we
must be cautious in interpreting your data obtained with DIDS
in concentrations as high as l0 to 102 M. In other systems,
such as the large intestine, apical chloride-bicarbonate ex-
change is inhibited by concentrations of DIDS on the order of 5
to 10 p.M. With these high doses, you might disrupt the
membrane.
DR. BORSATTI: The experiment you refer to has been carried
out in red blood cell ghosts to evaluate DIDS' effect on band 3
protein phosphorylation, and not to challenge oxalate transport.
When we looked for a DIDS effect on red blood cell oxalate
transport, we used a 5 p.M concentration.
DR. GIUSEPPE MAscHIo (Chief and Professor of Nephrology,
Division of Nephrology, University Hospital, Verona): You
showed that at least three pharmacologic agents (amiloride,
hydrochlorothiazide, and GAGs) can interfere with band 3
phosphorylation and promote a fall in oxalate flux rate in red
blood cells. Which of these drugs is most specific to the
enzymatic system? Are you aware of any other agents that can
act at a cellular level in patients with recurrent calcium neph-
rolithiasis?
DR. BORSATTI: I am not sure it is important that we know
which of the three substances you mentioned is the most
specific inhibitor of red blood cell band 3 phosphorylation.
Rather, I think it is important that we know which of them is
most effective in lowering urinary oxalate. To this end, GAGs
are far more powerful than amiloride and hydrochlorothiazide.
In answer to your second question, nifedipine also lowers both
red blood cell steady-state self exchange and urinary output of
oxalate [137].
DR. LORIS BORGHI (Institute of Internal Medicine, University
Hospital, Parma): When you measured red blood cell oxalate
flux, you used a 10 mM sodium oxalate solution. In normal
plasma the concentration of oxalate is about 2 p.M, and thus in
your experiments red blood cells are incubated in a medium
with a concentration of oxalate about 500 times the physiologic
concentration. I wonder whether this unphysiologic concentra-
tion of oxalate alters cellular function and, in particular, the
permeability of the cellular membrane to oxalate.
DR. BORSATTI: To charge red blood cells we used the same
solution as did Cousin and Motais. A high concentration of
oxalate is necessary to appreciate the self exchange, because at
0°C the exchange rate of chloride is 500 times higher than that
of oxalate. We did not observe any significant modification of
red blood cell shape or volume, and there was no hemolysis.
Even if cellular functions are altered or if an increased passive
passage of oxalate occurs through the membrane in these
experiments, we still find a clear-cut difference between stone
formers and controls in oxalate handling by red blood cells.
DR. GIORGTO BAzZATO (Chief, Division of Nephrology, Urn-
berto I Hospital, Mestre-Venezia): Given the similarities among
red blood cells, gut cells, and proximal and distal tubular cells,
are there similarities with gastric cells? If so, did you find any
increase of gastric proton secretion in patients with the abnor-
mal red blood cell oxalate self exchange?
DR. BORSATTI: Monoclonal antibodies raised against red
blood cell band 3 protein cross-react with gastric oxintic cells,
so these cells do have a red blood cell band-3-related protein.
Your idea of looking for an abnormality in proton secretion in
the stomach in patients with an accelerated red blood cell
oxalate self exchange is excellent. We did not perform such a
study.
DR. BAZZATO: Have you studied the effect of proton-block-
ing agents on urinary oxalate excretion?
DR. BORSATTI: No.
DR. NATALE DE SANTO (Chi ef and Professor of Nephrology,
Division of Pediatric Nephrology, Federico II University,
Napoli): You suggested that urinary pH might be relevant in
calcium oxalate stone formation. Because ascorbic acid lowers
pH, do you think it is a further possible mechanism by which
vitamin C favors calcium oxalate nephrolithiasis? Can the same
mechanism be invoked for high protein intake?
DR. BORSATTI: In studies using the gel crystallization
method, calcium oxalate crystal growth and pH were inversely
correlated [138]; at high pH, the crystallization of calcium
oxalate dihydrate, which is less stable, seems to prevail over
that of calcium oxalate monohydrate [139]. So a high ascorbate
intake, as well as a high-protein diet, might facilitate calcium
oxalate precipitation. What I do not know is how much vitamin
C has to be ingested before urinary pH decreases. Maybe Dr.
Williams knows more about this issue.
DR. HIBBARD E. WILLIAMS (Professor of Medicine, School
of Medicine, University of California, Davis, California, USA):
We have studied the effect of oral ascorbate on urine composi-
tion, and specifically on urinary oxalate. We collected urines in
concentrated hydrochloric acid to be sure that there was little
nonenzymatic conversion of ascorbate to oxalate, so I cannot
answer Dr. De Santo's question. We gave as much as 10 glday
to several normal individuals. Our preliminary conclusion from
15 individuals is that the urinary excretion of oxalate is not
affected significantly by the ingestion of as much as 5 g of
ascorbic acid per day. At a vitamin C intake of 10 glday, a small
number of patients have a slight increase. Perhaps a few
patients, possibly those with some abnormalities in the gastro-
intestinal tract, do respond abnormally, but in most normal
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individuals, moderately large quantities of ascorbate do not
affect urinary oxalate. Let me switch to another substance,
namely, sulfate. Do you have any evidence of an abnormality in
the handling of sulfate in stone formers? If so, what role might
such an abnormality play in stone disease?
DR. BORSATTI: Studies on urinary sulfate in renal stone
disease are scanty. Urinary sulfate output seems to depend on
dietary intake of animal protein, and a fairly good positive
correlation between sulfate and GAG excretion appears to be
the rule [1401. A positive correlation between sulfate and
calcium in the urine also has been reported [141], but I am not
aware of any relationship found with oxalate. As I have shown,
however, oxalate uptake from peritubular fluid occurs in ex-
change with sulfate, which means that an increased secretion of
oxalate should be paralleled by an increased absorption of
sulfate. We have no data yet on tubular sulfate handling in stone
formers with high red blood cell oxalate self exchange.
DR. MARTINO MARANGELLA (Director, Renal Stone Labora-
tory, Mauriziano Hospital, Torino): You have pointed out that
oxalate secretion by the proximal tubule might be affected by
sulfate and that GAGs' concentration and their degree of
sulfation can affect the oxalate self exchange in red blood cells.
Moreover, you have suggested that a low urinary pH can occur
in patients with pure calcium oxalate stones, and that sulfate,
GAGs, the degree of GAG sulfation, and urine pH all are
affected by animal proteins [142]. Have you studied the possible
influence of animal protein intake on the red blood cell self
exchange? Is there a possible role for animal protein intake in
your hypothesis?
DR. BoRsArrI: Animal protein intake does not affect the
steady-state oxalate self exchange in red blood cells. A high
animal protein intake increases both sulfate and GAG excre-
tion. The first step in moving oxalate from peritubular fluid to
the lumen is an uptake in exchange with sulfate; the more
sulfate that is reabsorbed, the more oxalate is secreted. By this
mechanism, a diet high in animal protein could stimulate
urinary oxalate excretion. However, we have evidence that
exogenous GAG administration lowers urinary oxalate, and the
same result should be obtained following an increase in the
urinary excretion of GAGs as occurs with high animal protein
intake. To summarize, sulfate and GAGs should have opposing
effects on oxalate renal handling.
DR. GlAcoMo CoLussi (Division of Nephrology, Niguarda-
Ca' Granda Hospital, Milan): You have hypothesized that,
based on structural identity between the band 3 protein residing
in red blood cells and alpha intercalated cells of the collecting
tubule, increased oxalate self exchange in erythrocytes could be
associated with increased C1/HC03 exchange in the collect-
ing tubule; thus, one would expect an increased acidification
capacity (that is, proton secretion) of the distal tubules, and
indeed you have suggested that a lower urinary pH in calcium
oxalate stone formers might support this possibility. However,
a lower urine pH might reflect diminished buffer availability
(that is, ammonia and/or phosphate) rather than increased
proton secretion. In fact, when proton secretion in calcium
stone formers was investigated by acid loading or by the
measurement of pCO2 in alkaline urines, a high incidence (up to
40%) of acidification defects (defined as incomplete type-i renal
tubular acidosis) has been observed [143, 1441. How can you fit
these observations with your hypothesis?
DR. BORSATTI: Concerning urinary pH in patients with pure
calcium oxalate stones, I have quoted data presented by Rob-
ertson et al [127]. We should appreciate that the prototypical
stone formed by patients with renal tubular acidosis contains
calcium phosphate, not calcium oxalate. Yet you are correct in
asserting that an incomplete distal renal tubular acidosis has
been observed in a high proportion of calcium stone formers.
The problem is: were they pure calcium oxalate stone formers?
Putting aside this consideration, I can conceive a defect in
excreting a proton load in patients suppposed to have an
alpha-intercalated cell band 3 protein working at a faster rate.
Just a small difference between actual rate and maximal possi-
ble rate might reduce the quantity of proton secreted after a
load.
DR. RENATA CAUDARELLA (Associate Professor of Meta-
bolic Diseases, Institute of Internal Medicine, University Hos-
pital, Bologna): You observed an increased rate of red blood
cell oxalate self-exchange in approximately 68% of patients, but
you could not find any relationship between the oxalate self-
exchange rate and the 24-hour urinary oxalate excretion. How
do you explain this observation? Might it be accounted for by
an overlap of several genetic and environmental factors, such as
dietary intake of proteins?
DR. BORSATTI: I do not believe that a defect in cellular
handling of oxalate is the single mechanism responsible for
stone formation. I do believe we have enough data to support
the view that many calcium oxalate stone formers have a defect
in oxalate transport at a cellular level, and that is all. It is likely
that other genetic or environmental factors contribute to the
development of nephrolithiasis, and a diet rich in animal protein
might be one of these factors. Today, blaming a high-protein
diet for stone formation is fashionable, but a definitive link
between dietary protein intake and nephrolithiasis is far from
established [28].
DR. JEROME P. KASSIRER (Associate Physician-in-Chief, De-
partment of Medicine, New England Medical Center, Boston,
Massachusetts, USA): A fundamental premise of your argu-
ment depends on exaggerated urinary oxalate excretion in
patients with calcium oxalate stone formation. Yet published
data show considerable variability in oxalate excretion in such
patients, and in many total urinary oxalate is normal. You argue
that even when total excretion is normal, diurnal variations in
excretion may yield high urinary oxalate concentrations during
part of the day. How convincing is the evidence for an in-
creased excretion of oxalate at some time during the day? Do
such patterns correlate with abnormalities in red blood cell
oxalate transport?
DR. BORSATTI: The appearance of peaks of urinary oversat-
uration with calcium oxalate sometime during the day is the rule
even in normal subjects. The urinary oxalate level fluctuates
during the day both in stone formers and in normal subjects.
The excretion is highest 2 or 3 hours after a meal, and this
postprandial increase is more pronounced in stone formers
[145]. We did carry out an oxalate tolerance test in five pairs of
brothers. One of each brother had an abnormal red blood cell
oxalate self exchange, but all had normal excretions of oxalate.
We found that the increase in urinary oxalate was significantly
higher at 2 and 4 hours after the oral oxalate load in the brothers
with the red blood cell abnormality [36].
Da. ANDREA TASCA (Institute of Urology, University Hospi-
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tal, Padova): To follow up Dr. Kassirer's question, how many
patients with an abnormal red blood cell oxalate self exchange
were hyperoxaluric? Have you observed hyperoxaluric stone
formers with a normal red blood cell self exchange?
DR. BORSATTI: As far as 24-hour urinary oxalate is con-
cerned, about 30% of patients with an abnormal red blood cell
oxalate self exchange were hyperoxaluric, as well as 9% of
patients with a normal red blood cell oxalate self exchange.
Whereas it appears easy to propose oversaturation peaks during
the day as a cause of stone formation in patients with abnormal
red blood cell self exchange and normal 24-hour urinary ox-
alate, the observation that some patients with a normal self
exchange are hyperoxaluric is intriguing. As I suggested earlier,
I believe that an abnormality in oxalate handling at a cellular
level is not a conditio sine qua non for hyperoxaluria to take
place. What brings hyperoxaluria about in patients with normal
red blood cell oxalate self exchange? Although I have no proof,
I suspect that a high dietary oxalate intake or even a subtle
abnormality in endogenous oxalate synthesis might be in-
volved.
DR. SURIAN: If postprandial episodes of oversaturation of
calcium oxalate have a crucial role in stone formation rather
than the state of saturation in a 24-hour urine collection, do you
think that the determination of urinary oxalate after a standard
oxalate meal could be a better diagnostic tool than the measure-
ment of oxalate in a 24-hour urine collection?
DR. BORSATTI: Most oxalate uptake from the gut occurs
within 8 hours after ingestion, and to date nobody has demon-
strated a difference in urinary oxalate between stone formers
and normal subjects during fasting, If a defect in oxalate
handling by stone formers is to be identified, it should be more
appropriate to evaluate urinary oxalate during the 8 hours
following a standard oxalate-rich meal.
DR. TASCA: Approximately one-third of hyperoxaluric pa-
tients have other urinary abnormalities such as hypercalciuria
and hyperuricosuria. Is there a connection in these patients
between red blood cell oxalate self exchange alterations and
these abnormalities?
DR. BORSATTI: Hypercalciuria was present in 27% and hyper-
uricosuria in 16% of our patients with an abnormal red blood
cell oxalate self exchange. I cannot exclude that cellular han-
dling of oxalate, urate, and calcium are in some way intercon-
nected. One can construct an elaborate hypothesis based on
several observations. First, for oxalate and urate to cross the
cell wall, both need an exchanger, which probably must be
activated to work. Second, calcium is an extremely important
intracellular messenger. Thus we could speculate that an in-
crease in free intracellular calcium is the primary defect, which
leads to activation of both oxalate and urate exchanger.
Da. FRANCESCO PAOLO SCHENA (Chief and Professor of
Nephrology, Division of Nephrology, University Hospital,
Ban): Did you find any correlation between sodium and oxalate
excretion in the urine? My question is based on the notion that
excretion of oxalate could be related to that of sodium. If so, the
quantity of sodium in the diet might be an important factor.
DR. BORSATTI: We did not look for a relationship between
sodium and oxalate in stone formers, and I do not even know
whether such a correlation exists in a normal population. Natale
De Santo recently carried out a careful epidemiologic investi-
gation on urinary constituents in the young population of a
village near Naples, and he might be able to provide some data.
DR. DE SANTO: Weconducted an epidemiologic investigation
on urinary oxalate excretion in all the young population of
Cimitile, a tiny village near Naples. We studied 220 children
aged 3 to 16 years. Twenty-four-hour oxalate excretion was
32.2 16,8 mg (mean SD) or 1.0 0.6 mg/kg body weight.
Oxaluria was not related to gender, but it correlated positively
with age (r = 0.37; P < 0.001), height (r = 0.42; P <0.001) and
body-mass index (r = 0.360; P < 0.001). No correlation was
found with weight (r = 0.126; not significant). As far as other
urinary constituents were concerned, we found a positive
correlation with calcium (P < 0.005), phosphate (P < 0.005),
magnesium (P < 0.001), creatinine (P < 0.008), potassium (P <
0.002) and sodium (P <0.002). The clinical significance of these
correlations is yet to be assessed.
DR. SCHENA: in your studies you have demonstrated genetic
transmission of the red blood cell defect. Does gender deter-
mine stone formation?
DR. BORSATTI: From the family study we performed, it was
clear that many females who had the abnormality of red blood
cell oxalate self exchange never formed stones; on the contrary,
almost all males with the red blood cell abnormality were stone
formers. Because male sex hormones increase the activity of
enzymes involved with oxalosynthesis, basal urinary excretion
of oxalate in males might be higher, and when peaks of
hyperoxaluria—possibly due either to intestinal hyperabsorp-
tion or renal oversecretion or both—occur, they could have a
larger impact on urinary oversaturation with calcium oxalate.
DR. ANGELA D'ANGELO (Associate Professor of Nephrol-
ogy, Institute of Internal Medicine, University Hospital, Pa-
dova): Recurrence of hypercalciuria in patients with renal
stones is not unusual after successful parathyroidectomy. In
some of these patients, hypercalciuria seems to be due to
intestinal calcium hyperabsorption. Do you think that mild
hyperoxaluria might be linked to this metabolic abnormality in
the case you presented?
DR. BORSATTI: The patient I described became normocalci-
uric after parathyroidectomy and was still so during the second
observation (262 mg/day). Nevertheless, there must be some-
thing common in intestinal absorption of calcium and oxalate.
This view is strengthened by the demonstration by Marangella
et al that a statistically significant increase in intestinal oxalate
absorption after an oral oxalate load was evident only in
patients who were hypercalciuric [301. Furthermore, vitamin D
administration increases dietary oxalate absorption in normal
subjects [146]. The common interpretation is that vitamin D, by
increasing calcium absorption, results in less binding of calcium
to oxalate in the intestine and makes more free oxalate available
for absorption. What we do not know is whether vitamin D has
a direct effect on oxalate handling by the cell.
DR. PAOLO MORACCHIELLO (Division of Nephrology, Urn-
berto I General Hospital, Mestre-Venezia): Do you have data
on red blood cell oxalate self exchange in patients with primary
hyperparathyroidism before and after parathyroidectomy?
DR. B0RsATrI: As a rule, oxalate red blood cell self exchange
is normal in primary hyperparathyroidism 136], and it remains
unchanged after parathyroidectomy.
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